Switch theme
Sign up to access all valuation multiples
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
2004
49
LTM Revenue n/a
LTM EBITDA -$18.8M
-$16.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PHAXIAM Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$18.8M.
In the most recent fiscal year, PHAXIAM Therapeutics achieved revenue of n/a and an EBITDA of $3.8M.
PHAXIAM Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PHAXIAM Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$49.7M | $3.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | Infinity% | XXX | XXX | XXX |
| Net Profit | n/a | -$57.8M | XXX | XXX | XXX |
| Net Margin | NaN% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PHAXIAM Therapeutics's stock price is EUR 1 (or $1).
PHAXIAM Therapeutics has current market cap of EUR 6.8M (or $7.3M), and EV of -EUR 15.0M (or -$16.1M).
See PHAXIAM Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$16.1M | $7.3M | XXX | XXX | XXX | XXX | $-1.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PHAXIAM Therapeutics has market cap of $7.3M and EV of -$16.1M.
PHAXIAM Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.9x LTM EBITDA.
Analysts estimate PHAXIAM Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PHAXIAM Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$16.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | XXX | XXX |
| P/E | -29.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPHAXIAM Therapeutics's NTM/LTM revenue growth is Infinity%
PHAXIAM Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.
Over next 12 months, PHAXIAM Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PHAXIAM Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PHAXIAM Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -108% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PHAXIAM Therapeutics acquired XXX companies to date.
Last acquisition by PHAXIAM Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . PHAXIAM Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PHAXIAM Therapeutics founded? | PHAXIAM Therapeutics was founded in 2004. |
| Where is PHAXIAM Therapeutics headquartered? | PHAXIAM Therapeutics is headquartered in France. |
| How many employees does PHAXIAM Therapeutics have? | As of today, PHAXIAM Therapeutics has 49 employees. |
| Is PHAXIAM Therapeutics publicy listed? | Yes, PHAXIAM Therapeutics is a public company listed on PAR. |
| What is the stock symbol of PHAXIAM Therapeutics? | PHAXIAM Therapeutics trades under PHXM ticker. |
| When did PHAXIAM Therapeutics go public? | PHAXIAM Therapeutics went public in 2013. |
| Who are competitors of PHAXIAM Therapeutics? | Similar companies to PHAXIAM Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of PHAXIAM Therapeutics? | PHAXIAM Therapeutics's current market cap is $7.3M |
| What is the current EBITDA of PHAXIAM Therapeutics? | PHAXIAM Therapeutics's last 12-month EBITDA is -$18.8M. |
| What is the current EV/EBITDA multiple of PHAXIAM Therapeutics? | Current EBITDA multiple of PHAXIAM Therapeutics is 0.9x. |
| Is PHAXIAM Therapeutics profitable? | Yes, PHAXIAM Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
